1488-96-6

Usage

Uses

Used in Pharmaceutical Industry:
1H-1,2,4-Triazole-1-carboxamide,2-amino-N-methyl-(9CI) is used as a building block for the development of new drugs. Its unique chemical structure allows for the creation of novel therapeutic agents with potential applications in treating various diseases and conditions. 1H-1,2,4-Triazole-1-carboxamide,2-amino-N-methyl-(9CI)'s reactivity and functional groups can be further modified to enhance its pharmacological properties and improve its efficacy and safety.
Used in Agricultural Chemicals Industry:
1H-1,2,4-Triazole-1-carboxamide,2-amino-N-methyl-(9CI) is utilized as a precursor in the synthesis of new pesticides. Its chemical properties make it suitable for the development of innovative agrochemicals with improved performance and selectivity. By incorporating 1H-1,2,4-Triazole-1-carboxamide,2-amino-N-methyl-(9CI) into the design of new pesticides, researchers can potentially create more effective and environmentally friendly solutions for crop protection and pest management.

InChI:InChI=1/C4H7N5O/c1-6-4(10)9-3(5)7-2-8-9/h2H,1H3,(H,6,10)(H2,5,7,8)

Upstream product

• 61-82-5 3⁽⁵⁾-amino-1,2,4-triazole 
• 624-83-9 methyl isocyanate 

Relevant academic research and scientific papers

Triazole derivative and pharmaceutical use thereof

An agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, an agent for the prophylaxis and treatment of allergic diseases, an agent for the prophylaxis and treatment of eosinophil-related diseases and an eosinophilia inhibitor, comprising, as an active ingredient, a series of triazole derivatives of the following formula (I) STR1 or the following formula (III) STR2 wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. A novel monocyclic or bicyclic triazole derivative. The agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, the agent for the prophylaxis and treatment of allergic diseases, the agent for the prophylaxis and treatment of eosinophil-related diseases, the eosinophilia inhibitor and the novel triazole derivative of the present invention all, have superior eosinophilia-inhibitory action and lymphocyte activation-inhibitory action. They are low toxic and persistent in action. They are particularly effective in the treatment of accumulation and activation of eosinophil and lymphocytes, inflammatory respiratory tract diseases, eosinophil-related diseases such as eosinophilia, and immune-related diseases.

Synthesis and pharmacological activity of triazole derivatives inhibiting eosinophilia

In order to develop novel antiasthmatic agents based on a new mechanism of action, a series of 3-substituted 5-amino-1- [(methylamino)(thiocarbonyl)]-1H-1,2,4-triazole derivatives were synthesized and evaluated in a model in which eosinophilia was induced in the airway through intravenous (iv) injection of Sephadex particles on days 0, 2, and 5. After screening of several hundred derivatives, we finally identified the highly potent eosinophilia inhibitor 5-amino-3-(4-chlorophenyl)-1- [(methylamino)(thiocarbonyl)]-1H-triazole (23c, GCC-AP0341), which had ID50 values of 0.3 and 0.07 mg/kg when administered orally (os) and intraperitoneally (ip), respectively. This compound showed complete inhibition of the hypersensitivity induced by ascaris inhalation at an ip dose of 1 mg/kg as well as low toxicity, with an LD50 value of >2.0 g/kg in mice. Extensive study of its mechanism of action revealed that 23c inhibited eosinophil survival induced by interleukin-5 (IL-5), but had little or no effect on leukotriene D4 (LTD4) or platelet-activating factor (PAF)- induced responses. Taken together, these results suggest 23c as a novel candidate for the treatment of chronic asthma. Further studies are now underway.